PDF Cover

Odevixibat Market

Odevixibat Market

The market for Odevixibat was estimated at $291 million in 2024; it is anticipated to increase to $418 million by 2030, with projections indicating growth to around $565 million by 2035.

Report ID:DS1802171
Author:Debadatta Patel - Senior Consultant
Published Date:April 2025
Datatree
Life Science
Pharmaceutical
Odevixibat
Share
Report Summary
Table of Contents
Methodology
Market Data

Global Odevixibat Market Outlook

Revenue, 2024

$291M

Forecast, 2034

$531M

CAGR, 2024 - 2034

6.2%
The Odevixibat industry revenue is expected to be around $309.6 million in 2025 and expected to showcase growth with 6.2% CAGR between 2025 and 2034. The progression in Odevixibats market worth underlines its increasingly significant role within the pharmaceuticals sector. One of the critical propellants of this advancement is an escalating international demand owing to its pivotal role in treating rare gastrointestinal diseases. The ongoing relevance of Odevixibat can be accredited to substantial advances in healthcare services, burgeoning investments in research & development, and escalating awareness about the potency of cutting-edge therapeutics. These influencing factors collectively contribute to the prevalence of Odevixibat in the market and are anticipated to continue bolstering its demand in upcoming years.

Odevixibat is a distinguished therapeutic drug primarily known for its role in tackling progressive familial intrahepatic cholestasis (PFIC) and other rare pediatric cholestatic liver diseases. Its unique features include its innovative mechanism of actiontargeting the ileal bile acid transporter (IBAT), resulting in reduced reabsorption of bile acids.

Odevixibat market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034

Market Key Insights

  • The Odevixibat market is projected to grow from $291.5 million in 2024 to $532 million in 2034. This represents a CAGR of 6.2%, reflecting rising demand across Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC), Management of Alagille Syndrome and Therapy for Biliary Atresia.
  • Albireo Pharma Inc., Mirum Pharmaceuticals, Novartis AG are among the leading players in this market, shaping its competitive landscape.
  • U.S. and Japan are the top markets within the Odevixibat market and are expected to observe the growth CAGR of 4.0% to 6.0% between 2024 and 2030.
  • Emerging markets including Brazil, Philippines and South Africa are expected to observe highest growth with CAGR ranging between 7.1% to 8.6%.
  • Transition like Expansion in Therapeutic Domains is expected to add $31.7 million to the Odevixibat market growth by 2030
  • The Odevixibat market is set to add $240 million between 2024 and 2034, with manufacturer targeting Biliary Atresia & Alagille Syndrome Therapeutic Application projected to gain a larger market share.
  • With Expanding role in progressive familial intrahepatic cholestasis treatment, and Broadening applications in cholestatic liver diseases, Odevixibat market to expand 82% between 2024 and 2034.
odevixibat market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032

Opportunities in the Odevixibat

The growth trajectory of Odevixibat is promising in emerging markets, particularly in Asia. Strengthening strategic collaborations with local partners and regulatory authorities could accelerate the availability and awareness of Odevixibat.

Growth Opportunities in North America and Europe

North America Outlook

In the North American market, Odevixibat exhibits a significant scope with its increasing prominence in the pharmaceutical sector. This growth is predominantly driven by extensive research and growing demand in the treatment of PFIC and other cholestatic liver diseases. Consequently, top opportunities lie in clinical developments and strategic partnerships with research institutions. The presence of robust pharmaceutical industries and health infrastructure further fuels the demand in this region. However, the competitive landscape is aggressively becoming denser with companies investing more in research and development activities to innovative treatments. Advanced healthcare services and high prevalence of rare and chronic diseases also act as powerful growth stimulants for Odevixibat in North America.

Europe Outlook

The European sector presents a robust market for Odevixibat, with an increasing number of recognized uses in treating Alagille syndrome and biliary atresia. The robust pharmaceutical framework, coupled with high awareness levels about rare diseases and their treatment, propels the demand for Odevixibat in this region. Top opportunities in Europe revolve around expanding approved applications for the drug and capitalizing on unmet medical needs. Factors such as the rise in extensive healthcare systems and significant increase in R&D initiatives emphasize the need for Odevixibat, thereby driving its market growth.

Market Dynamics and Supply Chain

01

Driver: Expanding Role in Progressive Familial Intrahepatic Cholestasis Treatment, and Technological Advancements in Drug Delivery Systems

As a foremost medication, Odevixibat targets the treatment for Progressive Familial Intrahepatic Cholestasis , a rare genetic disorder. This therapeutic application is also poised to be a key market given the unmet medical needs and the shortage of effective treatments for PFIC. The expanding role of Odevixibat in PFIC promises to fuel its market demand, creating increased opportunities in the pharmaceutical sector. Alongside the widening treatment applications, technological advancements in drug delivery systems are also set to influence Odevixibat market growth positively. The development and utilization of these advanced drug delivery methods, particularly suitable for Odevixibat, promise higher therapeutic efficacy and patient compliance, thereby serving as a crucial market growth facilitator.
Extensive research is also in progress to unravel the potential of Odevixibat in treating other cholestatic liver diseases. This broadening application spectrum underpins a significant market as it could also potentially offer an effective treatment alternative for a variety of liver diseases, thereby expanding the scope of Odevixibats industry reach.
02

Restraint: High Drug Development and Regulatory Costs

The development, testing, and regulation of new drugs such as Odevixibat present significant challenges. These high costs can limit the number of viable producers and subsequent market competition in the pharmaceutical industry. For instance, the expenses involved in exploratory studies, preclinical development, clinical testing and trials, and obtaining regulatory approval discourage potential players, consequently affecting the overall market trend for other stakeholders. This prohibitive financial base acts as a for the Odevixibat market, subsequently impacting the market demand and dynamics.
03

Opportunity: Technological Advancements in Drug Delivery and Odevixibats Potential in Pioneering Treatments

The pharmaceutical industry is exponentially benefiting from technological advancements in drug delivery systems. With Odevixibat, There is an for innovation utilizing these advancements to expand the drugs application horizon. For example, more precise, targeted delivery systems could enhance the efficiency and effectiveness of Odevixibat, dramatically improving patient outcomes.
As a novel, first-in-class treatment, Odevixibat has a promising, untapped to dominate the market for progressive familial intrahepatic cholestasis . With minimal competition and pressing unmet patient needs, incorporating Odevixibat into mainstream patient-care could provide relief to many patients suffering from this rare, life-threatening condition.
04

Challenge: Limited Awareness and Market Penetration

Despite the extraordinary potential of Odevixibat, the level of market awareness and penetration remains relatively low, especially in remote areas and developing nations. This limited exposure inhibits the market growth of Odevixibat and impacts the established market dynamics.

Supply Chain Landscape

1
Raw Material Providers

Cayman Chemical

MedKoo Biosciences

2
API & Intermediate Manufacturers

Albemarle Corporation

AstraZeneca

3
Formulation & Drug Developers

Mirum Pharmaceuticals

Albireo Pharma

4
End Consumer Industry

Gastroenterology

Pediatric Diseases

*The illustration highlights the key stakeholders within the supply chain ecosystem.

Applications of Odevixibat in Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC), Management of Alagille Syndrome & Therapy for Biliary Atresia

Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC)

Odevixibat is widely used in the treatment of PFIC, a genetic disorder that leads to progressive liver disease. It is an inhibitor of the ileal bile acid transporter and acts by reducing the reuptake of bile acids to the liver, thereby mitigating the effects of the disease. Key industry players like Albireo Pharma have gained significant market traction due to their focus on such innovative therapies.

Therapy for Biliary Atresia

Another application of Odevixibat lies in offering effective treatment for biliary atresia, a childhood disease of the liver. In these instances, the use of Odevixibat aids in improving the flow of bile by curbing the functioning of the IBAT. The therapeutic impact demonstrated by Odevixibat in treating this disease has further solidified its position within the pharmaceutical market.

Management of Alagille Syndrome

Odevixibat also plays an integral role in managing Alagille Syndrome, a genetic disorder that can adversely affect the liver, heart, and other parts of the body. Suppression of IBAT via Odevixibat aids in mitigating the accumulation of bile acid, thereby managing the symptoms of this syndrome.

Recent Developments

December 2024

Albireo Pharma, a prominent provider of Odevixibat, created a groundbreaking advancement by introducing a nano-formulation of the medication, ensuring a more efficient delivery system and improved patient compliance.

October 2024

Pharmaceutical major Johnson & Johnson announced a strategic partnership with Albireo Pharma to explore Odevixibat based therapeutics for liver diseases; a move expected to increase Odevixibats market reach.

July 2024

FDA approved a new indication for the use of Odevixibat in adult patients with primary biliary cholangitis, broadening the drugs application and increasing market potential for manufacturers like Albireo Pharma.

Odevixibat, a helpful drug in the treatment of progressive familial intrahepatic cholestasis , been making significant strides. There has been a noticeable surge in its demand, indicative of established market dynamics and novel technologies associated with its production and application.

Impact of Industry Transitions on the Odevixibat Market

As a core segment of the Pharmaceutical industry, the Odevixibat market develops in line with broader industry shifts. Over recent years, transitions such as Expansion in Therapeutic Domains and Regulatory Approvals Steering Growth have redefined priorities across the Pharmaceutical sector, influencing how the Odevixibat market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Expansion in Therapeutic Domains

Odevixibat, a novel nonsystemic ileal bile acid transport inhibitor has been primarily associated with the pharmaceutical industry, delivering promising results in treating progressive familial intrahepatic cholestasis and Alagille syndrome. It significantly reverses the symptoms by modifying the bile acid flow, making it particularly effective against bile acidrelated disorders. The manufacturers strategic shift to pediatric cholestasis, where alternative treatments are scarce, demonstrates industry transitions resulting from the medicines unique mechanism. This transition has spurred developments within the pharmaceutical industry, as it has incentivized other players to venture into the realm of orphan diseases, thereby enriching the existing therapeutic apparatus. This industry transition is expected to add $31.7 million in the industry revenue between 2024 and 2030.
02

Regulatory Approvals Steering Growth

The FDA acceptance of Odevixibats New Drug Application and subsequent priority reviews serve as potent industry transitions. Such strides in regulatory recognitions have augmented the market share of Odevixibat, aiding the players who collaborate or are involved in the medicines production and distribution.

Related Reports

Loading related reports...